Anti HIV drug is being tested on human to checkout its therapeutic effects ans safety. The new drug contains substance derived from a genetically developed plant. It has not been named yet.
Drug contains protein called as monoclonal antibodies. These bodies are derived from a plant which is genetically modified. Drug developers believe that the drug can treat HIV infection. A research study has further delighted developers by stating that affordable production of such antibodies is possible.
It is unknown whether FDA has approved this trial. But in UK trial is going on with approval from MHRA- a UK government regulatory body.
Trial is a part of a project initiated 7 years back known as Pharma-Planta. Goal of this project is to use genetically modified plants for development of drugs that are not feasible to manufacture at low cost. These medicines, highly effective also, can be of great help in developing countries where people can't afford high cost drugs.
WHO estimates death toll around 1.7 millions children of age below 5 years. The cause of death is disease that is preventable by vaccine. ed medicine
The antibodies are derived from GM plants of tobacco. These plants were grown in-house in Germany. In house farming of plants significantly reduces risk of contamination to other plants.
Production of antibodies from GM plants is much cheaper than the production of same antibodies by conventional method" says Julia Ma, co-coordinator of Pharma-Planta project.
The Trial
The trial includes eleven women. Two women of them were administered by antibodies and one with dummy. Intention of the trial is only to ensure antibodies (P2G12) are not harmful.
Drug contains protein called as monoclonal antibodies. These bodies are derived from a plant which is genetically modified. Drug developers believe that the drug can treat HIV infection. A research study has further delighted developers by stating that affordable production of such antibodies is possible.
It is unknown whether FDA has approved this trial. But in UK trial is going on with approval from MHRA- a UK government regulatory body.
Trial is a part of a project initiated 7 years back known as Pharma-Planta. Goal of this project is to use genetically modified plants for development of drugs that are not feasible to manufacture at low cost. These medicines, highly effective also, can be of great help in developing countries where people can't afford high cost drugs.
WHO estimates death toll around 1.7 millions children of age below 5 years. The cause of death is disease that is preventable by vaccine. ed medicine
The antibodies are derived from GM plants of tobacco. These plants were grown in-house in Germany. In house farming of plants significantly reduces risk of contamination to other plants.
Production of antibodies from GM plants is much cheaper than the production of same antibodies by conventional method" says Julia Ma, co-coordinator of Pharma-Planta project.
The Trial
The trial includes eleven women. Two women of them were administered by antibodies and one with dummy. Intention of the trial is only to ensure antibodies (P2G12) are not harmful.
No comments:
Post a Comment